# GILEAD SCIENCES, INC. (GILD) FY2024 Q1 P&L / Income Statement - Company: GILEAD SCIENCES, INC. (GILD) - Period: 2024-01-01 to 2024-03-31 - Filing: Q1 FY2024 10-Q, filed 2024-05-08, accession number 0000882095-24-000013 - Page: https://plicit.ai/financials/gild/fy2024-q1-income-statement - Chart image: https://plicit.ai/charts/gild-fy2024-q1-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2024-01-01 through 2024-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,686,000,000 US dollars - **Cost of goods sold**: 1,552,000,000 US dollars - **Gross profit (calculated)**: 5,134,000,000 US dollars - **Operating expenses (calculated)**: 9,456,000,000 US dollars - **Operating (loss) income**: negative 4,322,000,000 US dollars - **Other income (expense), net (calculated)**: negative 164,000,000 US dollars - **(Loss) income before income taxes**: negative 4,486,000,000 US dollars - **Income tax (benefit) expense**: negative 315,000,000 US dollars - **Net (loss) income**: negative 4,170,000,000 US dollars - **Tecartus - UNITED STATES**: 55,000,000 US dollars - **Tecartus - Rest of World**: 8,000,000 US dollars - **Tecartus - Europe**: 36,000,000 US dollars - **Total Cell Therapy - UNITED STATES**: 225,000,000 US dollars - **Total Cell Therapy - Rest of World**: 60,000,000 US dollars - **Total Cell Therapy - Europe**: 195,000,000 US dollars - **Yescarta - UNITED STATES**: 170,000,000 US dollars - **Yescarta - Rest of World**: 52,000,000 US dollars - **Yescarta - Europe**: 158,000,000 US dollars - **Total HIV - UNITED STATES**: 3,405,000,000 US dollars - **Total HIV - Rest of World**: 342,000,000 US dollars - **Total HIV - Europe**: 596,000,000 US dollars - **Biktarvy - UNITED STATES**: 2,315,000,000 US dollars - **Biktarvy - Rest of World**: 265,000,000 US dollars - **Biktarvy - Europe**: 365,000,000 US dollars - **Descovy - UNITED STATES**: 371,000,000 US dollars - **Descovy - Rest of World**: 29,000,000 US dollars - **Descovy - Europe**: 26,000,000 US dollars - **Genvoya - UNITED STATES**: 332,000,000 US dollars - **Genvoya - Rest of World**: 21,000,000 US dollars - **Genvoya - Europe**: 49,000,000 US dollars - **Odefsey - UNITED STATES**: 223,000,000 US dollars - **Odefsey - Rest of World**: 11,000,000 US dollars - **Odefsey - Europe**: 76,000,000 US dollars - **Other HIV - UNITED STATES**: 60,000,000 US dollars - **Other HIV - Rest of World**: 12,000,000 US dollars - **Other HIV - Europe**: 45,000,000 US dollars - **Revenue share - Symtuza - UNITED STATES**: 104,000,000 US dollars - **Revenue share - Symtuza - Rest of World**: 3,000,000 US dollars - **Revenue share - Symtuza - Europe**: 33,000,000 US dollars - **Total Liver Disease - UNITED STATES**: 385,000,000 US dollars - **Total Liver Disease - Rest of World**: 215,000,000 US dollars - **Total Liver Disease - Europe**: 137,000,000 US dollars - **Other Liver Disease - UNITED STATES**: 42,000,000 US dollars - **Other Liver Disease - Rest of World**: 19,000,000 US dollars - **Other Liver Disease - Europe**: 47,000,000 US dollars - **Sofosbuvir/Velpatasvir - UNITED STATES**: 248,000,000 US dollars - **Sofosbuvir/Velpatasvir - Rest of World**: 78,000,000 US dollars - **Sofosbuvir/Velpatasvir - Europe**: 79,000,000 US dollars - **Vemlidy - UNITED STATES**: 95,000,000 US dollars - **Vemlidy - Rest of World**: 119,000,000 US dollars - **Vemlidy - Europe**: 11,000,000 US dollars - **Total Oncology - UNITED STATES**: 431,000,000 US dollars - **Total Oncology - Rest of World**: 96,000,000 US dollars - **Total Oncology - Europe**: 262,000,000 US dollars - **AmBisome - UNITED STATES**: 14,000,000 US dollars - **AmBisome - Rest of World**: 60,000,000 US dollars - **AmBisome - Europe**: 70,000,000 US dollars - **Other - UNITED STATES**: 59,000,000 US dollars - **Other - Rest of World**: 12,000,000 US dollars - **Other - Europe**: 9,000,000 US dollars - **Total Other - UNITED STATES**: 73,000,000 US dollars - **Total Other - Rest of World**: 71,000,000 US dollars - **Total Other - Europe**: 79,000,000 US dollars - **Royalty, contract and other revenues - UNITED STATES**: 23,000,000 US dollars - **Royalty, contract and other revenues - Rest of World**: 1,000,000 US dollars - **Royalty, contract and other revenues - Europe**: 15,000,000 US dollars - **Trodelvy - UNITED STATES**: 206,000,000 US dollars - **Trodelvy - Rest of World**: 36,000,000 US dollars - **Trodelvy - Europe**: 68,000,000 US dollars - **Veklury - UNITED STATES**: 315,000,000 US dollars - **Veklury - Rest of World**: 169,000,000 US dollars - **Veklury - Europe**: 70,000,000 US dollars - **Product sales - UNITED STATES**: 4,609,000,000 US dollars - **Product sales - Rest of World**: 894,000,000 US dollars - **Product sales - Europe**: 1,144,000,000 US dollars - **Selling, general and administrative expenses**: 1,375,000,000 US dollars - **Acquired in-process research and development expenses**: 4,131,000,000 US dollars - **Research and development expenses**: 1,520,000,000 US dollars - **In-process research and development impairment**: 2,430,000,000 US dollars - **Revenue before reconciliation (calculated)**: 19,903,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 13,217,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Product and Service (16 categories) - Page: https://plicit.ai/financials/gild/fy2024-q1-income-statement/revenue-by-product-and-service-16-categories - Chart image: https://plicit.ai/charts/gild-fy2024-q1-revenue-by-product-and-service-16-categories-sankey.png Income statement for 2024-01-01 through 2024-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,686,000,000 US dollars - **Cost of goods sold**: 1,552,000,000 US dollars - **Gross profit (calculated)**: 5,134,000,000 US dollars - **Operating expenses (calculated)**: 9,456,000,000 US dollars - **Operating (loss) income**: negative 4,322,000,000 US dollars - **Other income (expense), net (calculated)**: negative 164,000,000 US dollars - **(Loss) income before income taxes**: negative 4,486,000,000 US dollars - **Income tax (benefit) expense**: negative 315,000,000 US dollars - **Net (loss) income**: negative 4,170,000,000 US dollars - **Tecartus**: 100,000,000 US dollars - **Yescarta**: 380,000,000 US dollars - **Biktarvy**: 2,946,000,000 US dollars - **Descovy**: 426,000,000 US dollars - **Genvoya**: 403,000,000 US dollars - **Odefsey**: 310,000,000 US dollars - **Revenue share - Symtuza**: 141,000,000 US dollars - **Other HIV**: 117,000,000 US dollars - **Sofosbuvir/Velpatasvir**: 405,000,000 US dollars - **Vemlidy**: 225,000,000 US dollars - **Other Liver Disease**: 107,000,000 US dollars - **Trodelvy**: 309,000,000 US dollars - **AmBisome**: 144,000,000 US dollars - **Other**: 80,000,000 US dollars - **Royalty, contract and other revenues**: 39,000,000 US dollars - **Veklury**: 555,000,000 US dollars - **Selling, general and administrative expenses**: 1,375,000,000 US dollars - **Acquired in-process research and development expenses**: 4,131,000,000 US dollars - **Research and development expenses**: 1,520,000,000 US dollars - **In-process research and development impairment**: 2,430,000,000 US dollars - **Revenue before reconciliation (calculated)**: 6,687,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/gild/fy2024-q1-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/gild-fy2024-q1-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2024-01-01 through 2024-03-31. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,686,000,000 US dollars - **Cost of goods sold**: 1,552,000,000 US dollars - **Gross profit (calculated)**: 5,134,000,000 US dollars - **Operating expenses (calculated)**: 9,456,000,000 US dollars - **Operating (loss) income**: negative 4,322,000,000 US dollars - **Other income (expense), net (calculated)**: negative 164,000,000 US dollars - **(Loss) income before income taxes**: negative 4,486,000,000 US dollars - **Income tax (benefit) expense**: negative 315,000,000 US dollars - **Net (loss) income**: negative 4,170,000,000 US dollars - **Product sales**: 6,647,000,000 US dollars - **Royalty, contract and other revenues**: 39,000,000 US dollars - **Selling, general and administrative expenses**: 1,375,000,000 US dollars - **Acquired in-process research and development expenses**: 4,131,000,000 US dollars - **Research and development expenses**: 1,520,000,000 US dollars - **In-process research and development impairment**: 2,430,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/gild/fy2024-q1-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/gild-fy2024-q1-revenue-by-geography-sankey.png Income statement for 2024-01-01 through 2024-03-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,686,000,000 US dollars - **Cost of goods sold**: 1,552,000,000 US dollars - **Gross profit (calculated)**: 5,134,000,000 US dollars - **Operating expenses (calculated)**: 9,456,000,000 US dollars - **Operating (loss) income**: negative 4,322,000,000 US dollars - **Other income (expense), net (calculated)**: negative 164,000,000 US dollars - **(Loss) income before income taxes**: negative 4,486,000,000 US dollars - **Income tax (benefit) expense**: negative 315,000,000 US dollars - **Net (loss) income**: negative 4,170,000,000 US dollars - **UNITED STATES**: 4,633,000,000 US dollars - **Europe**: 1,159,000,000 US dollars - **Rest of World**: 894,000,000 US dollars - **Selling, general and administrative expenses**: 1,375,000,000 US dollars - **Acquired in-process research and development expenses**: 4,131,000,000 US dollars - **Research and development expenses**: 1,520,000,000 US dollars - **In-process research and development impairment**: 2,430,000,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - The amounts that make up net income come to −$4,171.00 M and net income is −$4,170.00 M; the $1.00 M difference is within the rounding of the filed amounts.